,0,1
0,san francisco,9.0
1,applications thereto,9.0
2,neonatal sepsis,9.0
3,accounting pronouncements,8.596153846153847
4,balance sheets,8.545219638242894
5,step decision sequence,8.5
6,spectrum beta,8.428571428571429
7,accounting policies,8.396153846153846
8,therapeutic antibodies,8.384615384615385
9,authorize sublicenses related,8.362068965517242
10,medical officer,8.321428571428571
11,blood stream infections,8.295774647887324
12,owned subsidiary,8.285714285714285
13,operating officer,8.270547945205479
14,balance sheet,8.267441860465116
15,stock appreciation rights,8.255369928400954
16,inducement exemption,8.233333333333334
17,grade credit ratings,8.23076923076923
18,mdr acinetobacter baumannii,8.11111111111111
19,executive offices,8.092592592592592
20,pharmaceutical ingredient,8.0625
21,fide period,8.006993006993007
22,thermo fisher,8.0
23,consolidated statements,7.940891772217073
24,exercise dates,7.931506849315069
25,statistical superiority,7.9
26,raw materials,7.866666666666667
27,accounting policies,7.780364372469636
28,securities,7.777272727272727
29,income tax consequences,7.769230769230769
30,service period,7.756993006993007
31,substantial expenses,7.712969786293293
32,interest rate,7.6835607537361925
33,committed funding,7.674702667952427
34,shelf registration statement,7.673809523809523
35,substantial losses,7.6684782608695645
36,service fees,7.659090909090909
37,rise,7.568181818181818
38,positive data,7.567857142857142
39,united states,7.555555555555555
40,preferred stock,7.5494875754597786
41,product candidate,7.546511627906977
42,marketing authorization application,7.535714285714286
43,related notes,7.528735632183908
44,work plans,7.522197558268591
45,financial statements,7.479790373615675
46,unrecognized stock,7.4775921506231775
47,application methods,7.472222222222221
48,substantial expenditures,7.466555183946488
49,monthly payments,7.460917144346014
50,balance sheet arrangements,7.45740601817121
51,debt obligations,7.443486590038313
52,gross proceeds,7.439868462261195
53,operating plans,7.428869183715397
54,advanced research,7.420068728522337
55,annual period,7.41875771287536
56,melinda gates foundation,7.4172445677300045
57,stock options,7.376389036681209
58,stock options,7.376389036681209
59,stock options,7.376389036681209
60,broad enrollment,7.375
61,additional financing,7.37353228962818
62,charitable foundation,7.37029637029637
63,net proceeds,7.338265217138538
64,compensation costs,7.333730158730159
65,substantial research,7.323546989391901
66,comprehensive model,7.323153899240856
67,public offering,7.311567620445096
68,net loss,7.309924269108841
69,derivative instrument,7.3059163059163055
70,basis,7.3
71,accounting policy,7.291556145004421
72,bacterial infections,7.273552425665102
73,trial accruals,7.26302195436935
74,preclinical studies,7.260869565217391
75,common stock,7.247992879220626
76,commercial launch,7.246296296296297
77,signing fee,7.224206349206349
78,balance sheet classification,7.216936809960067
79,ill patients,7.213333333333333
80,commercialization rights,7.202865761689291
81,stock units,7.1996514533276414
82,simulation model,7.199494949494949
83,clinical trials,7.194372068785826
84,assets prepaids,7.193537056550755
85,fasb issued asu,7.190510465789691
86,trading day,7.1875
87,purpose discovery platform,7.179962894248609
88,product candidate,7.179844961240311
89,term investments,7.1490175621631025
90,qualified research,7.142137694039579
91,stock units,7.1398396253706515
92,market developments,7.122448979591837
93,financial statements,7.1137773017202495
94,external expenses,7.1105078593620235
95,expenses,7.106991525423728
96,sums,7.105092091007584
97,facility lease,7.102106227106227
98,financial covenants,7.096590909090909
99,bacterial infections,7.0963256120746525
100,royalties,7.084962406015038
101,reporting periods,7.075612486009202
102,related costs,7.0707991242474
103,unrealized gain,7.069951007076756
104,arm cohort,7.065217391304348
105,pricing model,7.063131313131313
106,term loans,7.061439473515781
107,stock awards,7.0582373119135
108,facility expenses,7.05044390637611
109,property rights,7.044117647058823
110,offering proceeds,7.0431313469478845
111,fluoroquinolone,7.04210236653825
112,financial statements,7.03534592917123
113,advance payments,7.0295261669024045
114,platform technology,7.0144300144300145
115,cash equivalents,7.007982929584536
116,stock awards,6.9984254839565105
117,important data,6.996428571428571
118,exercise price,6.9945699123781315
119,current assets,6.993537056550755
120,additional information,6.987734947435489
121,medicines agency,6.974025974025974
122,cre infections,6.970193252538487
123,equity offerings,6.967227564102564
124,fda granted fast,6.964627477785372
125,debt financing,6.962931034482759
126,monthly payments,6.954877454958611
127,financing arrangements,6.954810901001113
128,manufacturing processes,6.94927536231884
129,common stock,6.947992879220626
130,net sales,6.946362177605573
131,income taxes,6.94501763092595
132,balance sheet date,6.942901492759281
133,controlled study,6.9375
134,cash,6.929594905854467
135,cash requirements,6.92548048579177
136,sales proceeds,6.9147788565264285
137,physician market research,6.902517708114174
138,committed funding,6.89692489017465
139,cash flows,6.892846453157738
140,money market,6.890630797773655
141,antibiotic incentives,6.888888888888889
142,gram,6.886621315192743
143,financing requirements,6.88386524822695
144,notes thereto,6.8768115942028984
145,stock options,6.876389036681209
146,money market funds,6.867903525046382
147,net proceeds,6.866434231223044
148,additional financing,6.859246575342466
149,annual return,6.856209150326798
150,sublicense revenue payments,6.856038158560382
151,specific trial,6.855964325529543
152,credit risk,6.855769230769231
153,additional funding,6.8368893715914
154,asprepaid,6.833333333333333
155,priority review,6.832220943613349
156,drug candidates,6.827586206896552
157,money market,6.822448979591837
158,tax liabilities,6.813676835498468
159,equity incentive plans,6.80375393081761
160,liability instrument,6.801020408163265
161,health threat,6.794326241134752
162,cash dividends,6.789549749861034
163,period,6.780826678392602
164,payment accounting,6.773522503540466
165,financial statements,6.768679262504564
166,planned operations,6.755754323196184
167,marketing approval,6.754047619047618
168,financial statements,6.7496316434569446
169,cash,6.741234860525018
170,access commitments,6.74114774114774
171,aggregate amount,6.740404040404041
172,balance sheet,6.739664082687338
173,debt financing arrangements,6.730672969966629
174,stock compensation expense,6.7279889760200025
175,operating assets,6.718767943564925
176,committed funding,6.708949243294893
177,outstanding payments,6.7078685925018835
178,material agreement,6.693217944189332
179,antidilutive impact,6.6805509641873275
180,financial information,6.6621482467011734
181,additional funding,6.661697555734622
182,net headcount,6.659265201654108
183,stock options,6.652704826154894
184,work plans,6.633308669379701
185,principal amount,6.610774410774411
186,marketing approval,6.60981684981685
187,stock equivalents,6.609283201801271
188,recurring adjustments,6.6
189,term loan,6.582849587949151
190,foreseeable future,6.5817185274696826
191,resistant enterobacteriaceae,6.579690923768885
192,technology access fees,6.575757575757576
193,year service period,6.571425996683729
194,recurring measurements,6.560144927536232
195,current assets,6.555606022067996
196,market data,6.547448979591837
197,cash dividends,6.546692607003891
198,debt securities,6.545583508590928
199,development funding organizations,6.526143790849673
200,lease period,6.520454545454546
201,operating expenses,6.517625677525761
202,payable approximates,6.5148378191856455
203,cash flows,6.514468074779359
204,debt instruments,6.513351909903633
205,prevention,6.497948016415869
206,additional funds,6.491465826679363
207,funding requirements,6.474551522736755
208,lease agreement,6.469837377387713
209,equity awards,6.467013888888889
210,december31,6.464432989690722
211,success fee agreement,6.4520107595610945
212,volatility rate,6.446411483253589
213,net losses,6.445505330801811
214,public offering,6.444900953778429
215,life assumption,6.436842105263158
216,cash proceeds,6.434084922059272
217,approval,6.431653241273494
218,facility lease,6.427747252747253
219,expenses,6.4217756397768095
220,launch plazomicin,6.41958041958042
221,loan balances,6.409140667761358
222,additional funding,6.392789992709413
223,interest expense,6.3899024835471
224,safety concerns,6.388746803069053
225,net cash,6.384708882145915
226,registration statement,6.3839544513457565
227,regulatory approval,6.36955710955711
228,research organizations,6.369177639413426
229,fisher plan,6.360902255639098
230,time,6.3459631071560985
231,regulatory approval,6.33878787878788
232,direct costs,6.335907859078591
233,negative pathogens,6.328764478764478
234,efficacy data,6.325
235,interim periods,6.318795996467472
236,resistant gram,6.316739589388979
237,financial assets,6.31576899128269
238,potential funding,6.310635769459299
239,ivd assay,6.308469308469309
240,equity offering program,6.303699712643678
241,administrative expenses,6.297077732320281
242,compensation expense,6.297046528535079
243,related costs,6.2940134099616865
244,commercial validation,6.275084175084175
245,restricted cash,6.271229644040929
246,profit foundation grant,6.267787114845938
247,exercise price,6.263800681608901
248,purchase price,6.256611450159837
249,management,6.231829573934837
250,common stock,6.225770656998404
251,employee stock options,6.218494299839104
252,substantial research,6.208488664895613
253,average shares,6.208403183023872
254,payment defaults,6.203343938265755
255,retrospective basis,6.2
256,payment,6.191261084410749
257,term investments,6.1906842288297685
258,success fee&quot,6.169547964113181
259,default interest rate,6.168409238584678
260,equity offering,6.164810823754789
261,common stock,6.1415412663174
262,common shares,6.131795364612776
263,allotment option,6.125
264,remaining warrants,6.117238328413762
265,payment transactions,6.114868657386619
266,party collaboration funding,6.1134135472370765
267,lease cost,6.097726548813505
268,development expenses,6.091060152874709
269,maturity date,6.089601046435579
270,conduct,6.086514216155116
271,revenue,6.075546185312423
272,base rent,6.075359175928436
273,registration statement,6.048809523809524
274,clinical trial,6.045630650021524
275,estimated grant,6.043489190548015
276,discovery work,6.037895158063225
277,time improvement allowance,6.0207373271889395
278,valuation model,6.017676767676768
279,performance obligations,6.016594516594516
280,company,6.004986574606828
281,improvements allowance,6.001865622961513
282,milestone payments,5.991914491995648
283,capital resources,5.983390173045345
284,clinical evidence,5.981966053748232
285,securities exchange act,5.9772727272727275
286,private placement&quot,5.964682274247491
287,fair values,5.9571396062822055
288,atm equity program,5.919791666666667
289,monoclonal antibodies,5.908424908424909
290,receivable relate,5.904611211573236
291,carbapenem antibiotic,5.897435897435897
292,contract research,5.895052132979425
293,tenant,5.866640316205534
294,term loans,5.853635480775309
295,modified intent,5.849206349206349
296,stock award agreements,5.844380917411944
297,government contracts,5.831714929772845
298,effective date,5.828237410071942
299,indirect research,5.821735395189003
300,gates foundation,5.817244567730004
301,contract research organizations,5.816104764558373
302,significant judgments,5.812125249833445
303,gates purchase agreement,5.805264031848191
304,subsequent options,5.793896955071146
305,line data results,5.7867021276595745
306,term loan,5.7866515331304065
307,expenses,5.7704486109439515
308,year research term,5.768210638400852
309,based options,5.7636284073781034
310,term&quot,5.761083502127593
311,research,5.760017770285935
312,requirements,5.759493670886076
313,additional allowance&quot,5.755778666439774
314,litigation costs,5.75393811533052
315,additional disclosure,5.74853228962818
316,company term loans,5.744586967662839
317,options,5.7356548056941
318,funding support,5.73442132633016
319,efficacy endpoints,5.699999999999999
320,single study,5.676172447484123
321,solar capital,5.656217345872518
322,research program,5.637911865777239
323,development costs,5.629329441700344
324,securities purchase agreement,5.627196953295676
325,costs,5.613685636856369
326,key assumptions,5.611740672217083
327,contract funds,5.6096595955750885
328,sale securities,5.607174688057041
329,research,5.58497068930665
330,underwriting discounts,5.563467492260061
331,care trials,5.549707602339181
332,discovery research,5.499621065586195
333,balance sheet,5.489664082687339
334,patient enrollment,5.488636363636363
335,outstanding warrants,5.4540681652436
336,defined period,5.443356643356644
337,loan agreement,5.42048902043066
338,exercised option,5.373055279708706
339,term investments,5.3602851677969054
340,total revenue,5.356884397030383
341,derivative liabilities,5.356311902751531
342,purchase agreement&quot,5.32383726950121
343,treatment options,5.314483160567837
344,net consisted,5.279041916167664
345,inducement plan&quot,5.268148632450692
346,standard events,5.24969696969697
347,plazomicin,5.205294705294705
348,simulation model,5.19949494949495
349,facilities lease obligation,5.191239316239316
350,oral treatment,5.186111111111111
351,derivative liabilities,5.186078627255098
352,warrants,5.170159508790203
353,bacterial infections,5.162441314553991
354,approval change,5.155271395271395
355,consolidated statements,5.133199464524766
356,rsus,5.114635697413846
357,global access,5.098290598290598
358,management,5.086668283612256
359,consolidated subsidiary,5.063492063492063
360,development services,5.046568627450981
361,consolidated statement,5.034920634920635
362,prepaid expenses,5.021524045748932
363,fiscal years,5.016835016835017
364,services,5.013888888888889
365,thermo fisher,5.0
366,terms,4.971613628102178
367,credit facility,4.945054945054945
368,gross proceeds,4.939868462261196
369,adequate funding,4.9299719887955185
370,superiority,4.9
371,clinical candidate,4.889108910891089
372,charged directly,4.872844827586206
373,payment,4.852941176470589
374,net proceeds,4.838265217138538
375,share price change,4.808370852618641
376,interim reporting,4.804545454545455
377,antibacterial candidate,4.8
378,antibody platform,4.792207792207792
379,deferred taxes,4.791171477079796
380,options,4.776191522073359
381,tenant improvement,4.772727272727273
382,continued service,4.75
383,corporate headquarters,4.75
384,research programs,4.728314342557424
385,plazomicin development,4.720603973656138
386,monoclonal antibodies,4.717948717948718
387,financial statements,4.702012595837897
388,expenses,4.690039470629208
389,stock plans,4.689332192551898
390,advanced funds,4.6854545454545455
391,supportive data,4.675
392,meaningful data,4.675
393,committed funding,4.6747026679524275
394,registration statement,4.673809523809524
395,additional financing,4.659246575342466
396,remain outstanding,4.655172413793103
397,related party,4.6347962382445145
398,bloodstream infections,4.629107981220658
399,facility lease,4.627747252747253
400,include direct,4.611111111111111
401,oral antibiotics,4.611111111111111
402,stock payment,4.608311104871543
403,net loss,4.604041916167665
404,net losses,4.604041916167665
405,stock compensation,4.59465564268667
406,substantial doubt,4.586956521739131
407,substantial portion,4.586956521739131
408,platform technology,4.5858585858585865
409,medical meeting,4.571428571428571
410,provide important,4.571428571428571
411,cash,4.567525940337225
412,low single,4.565217391304348
413,profit foundation,4.561904761904762
414,interim periods,4.559302325581395
415,cancelable agreement,4.556375838926175
416,united states,4.555555555555555
417,contractual obligations,4.555555555555555
418,preferred stock,4.5494875754597786
419,drug,4.541229385307346
420,data,4.536111111111111
421,options,4.532783814162608
422,related expenses,4.53156049094097
423,net cash,4.525734523171556
424,work plans,4.522197558268591
425,operating segment,4.520547945205479
426,aggregate amount,4.518181818181818
427,drug application,4.508620689655173
428,financing activities,4.507978723404255
429,committed funds,4.504470938897168
430,accompanying notes,4.5
431,unrealized gains,4.5
432,awards,4.498538011695906
433,success fee,4.49563492063492
434,fee equal,4.494883040935672
435,financial instruments,4.494739057239057
436,capital,4.492224475997295
437,current intention,4.4743589743589745
438,discount rate,4.473684210526316
439,dividend rate,4.473684210526316
440,lower rate,4.473684210526316
441,calibration model,4.472222222222222
442,administrative expenses,4.469491525423729
443,plazomicin nda,4.466230122718672
444,common stock,4.447992879220626
445,total funding,4.437908496732026
446,discovering medicines,4.428571428571429
447,negative infections,4.417396269508945
448,gates foundation,4.4172445677300045
449,comprehensive loss,4.410714285714286
450,term loans,4.406267059722677
451,operating activities,4.403526668609735
452,options,4.3973348977539395
453,cash flows,4.392846453157738
454,resistant pathogens,4.3897515527950315
455,cash,4.388797870161786
456,antibodies,4.384615384615385
457,leases,4.380952380952381
458,stock options,4.37638903668121
459,broad enrollment,4.375
460,warrants,4.368957443878254
461,income taxes,4.364372469635628
462,interest income,4.36372269705603
463,closely related,4.362068965517242
464,related complications,4.362068965517242
465,teaes,4.362068965517242
466,deferred research,4.36071388981266
467,amount,4.360287081339713
468,interim period,4.356993006993007
469,related costs,4.356513409961686
470,costs,4.356513409961686
471,credit losses,4.355769230769231
472,expenses,4.3533995714007405
473,underwriting discounts,4.352941176470588
474,clinical studies,4.349978476108481
475,period,4.349098270150902
476,financial institution,4.346590909090909
477,interest expense,4.3432098765432094
478,compensation committee,4.339285714285714
479,expenses,4.336158192090395
480,microbiological eradication,4.333333333333334
481,average price,4.332293832293832
482,entirety,4.324427480916031
483,market exclusivity,4.322448979591837
484,resistant enterobacteriaceae,4.321070234113712
485,annual report,4.31917211328976
486,stock price,4.318432991464018
487,regulatory review,4.318181818181818
488,deferred revenue,4.317871438662586
489,related information,4.315557337610265
490,financial condition,4.31433284457478
491,offerings,4.311111111111111
492,directly identifiable,4.310344827586206
493,options,4.3085191082802545
494,issued asu,4.308157524613221
495,initial term,4.307042253521127
496,financial information,4.300079281183932
497,basis,4.3
498,profit foundations,4.3
499,commercial paper,4.296296296296296
500,commercial launch,4.296296296296296
501,commercial production,4.296296296296296
502,administrative costs,4.294444444444444
503,private placement,4.2907692307692304
504,interest method,4.286799620132953
505,debt instruments,4.286079182630907
506,resistant pathogen,4.282608695652174
507,factors,4.282051282051282
508,average period,4.276223776223777
509,values,4.275337837837838
510,existing cash,4.2739653342766175
511,net property,4.273159563226488
512,credit,4.272435897435898
513,sales taxes,4.26608187134503
514,initially measured,4.264285714285714
515,preclinical studies,4.260869565217391
516,3 studies,4.260869565217391
517,drug administration,4.258620689655173
518,drug compounds,4.258620689655173
519,measurements,4.25
520,biodefense,4.25
521,additional funding,4.24993284985227
522,funding,4.243855288594311
523,tax services,4.240384615384615
524,subsequent quarters,4.238095238095238
525,revenue,4.237226277372263
526,infections,4.2369511184755595
527,remaining term,4.2343149807938545
528,cash,4.234192607003891
529,private placements,4.230769230769231
530,infections,4.229658945407985
531,commercial validation,4.229629629629629
532,negative pathogens,4.228764478764479
533,fee,4.22420634920635
534,foreseeable future,4.219649561952441
535,government funding,4.215686274509804
536,provide signing,4.214285714285714
537,generated solely,4.211764705882353
538,interest rates,4.209876543209877
539,cash equivalents,4.207982929584536
540,additional expenses,4.203738100766195
541,mezzanine equity,4.203125
542,negative impact,4.201621621621621
543,clinical trials,4.194372068785826
544,current assets,4.193537056550755
545,tenant improvements,4.192727272727273
546,leases,4.187214611872146
547,commercial assay,4.185185185185185
548,active market,4.184948979591837
549,equity securities,4.1803977272727275
550,headcount,4.180223285486443
551,trial,4.173913043478261
552,care trial,4.173913043478261
553,threshold levels,4.166666666666666
554,based compensation,4.163713195201745
555,dividend equivalents,4.161290322580645
556,solar capital,4.156217345872518
557,milestone payments,4.155848918225156
558,outstanding rsus,4.155172413793103
559,front fee,4.152777777777778
560,final fee,4.152777777777778
561,mdr enterobacteriaceae,4.149572649572649
562,term investments,4.1490175621631025
563,future awards,4.1477541371158395
564,product,4.1465116279069765
565,lapse unexercised,4.142857142857142
566,recently announced,4.142857142857142
567,financial institutions,4.138257575757576
568,debt hosts,4.137931034482758
569,debt discount,4.137931034482758
570,debt financings,4.137931034482758
571,future periods,4.134834240475012
572,advantageous market,4.122448979591837
573,market participants,4.122448979591837
574,market activity,4.122448979591837
575,negative bacteria,4.121621621621621
576,call options,4.1210191082802545
577,management plans,4.118172790466733
578,subsequent events,4.118095238095238
579,product candidates,4.115477145148356
580,debt securities,4.1152037617554855
581,salaries,4.111111111111111
582,pathogens,4.107142857142858
583,care trials,4.105263157894736
584,allocated overhead,4.104166666666666
585,employee stock,4.09747519155885
586,epic trial,4.093913043478261
587,principal participant,4.092592592592593
588,current liabilities,4.092006033182503
589,credit,4.089743589743589
590,potential funding,4.088413547237077
591,lease term,4.087170458649332
592,clinical costs,4.083553355335534
593,additional allowance,4.081865622961513
594,working capital,4.080459770114942
595,additional funds,4.0797011207970115
596,commercial manufacturing,4.07890499194847
597,previously disclosed,4.076923076923077
598,drug discovery,4.0749472202674175
599,funding,4.074660633484163
600,fiscal year,4.073692248949981
601,fiscal year,4.073692248949981
602,fiscal year,4.073692248949981
603,funds,4.073623559539053
604,intercompany accounts,4.068181818181818
605,constitutes complete,4.066666666666666
606,financial assets,4.06576899128269
607,obtaining fda,4.063311688311688
608,exchange price,4.063063063063063
609,exit price,4.063063063063063
610,underlying price,4.063063063063063
611,related disclosures,4.062068965517241
612,warrants,4.056632267807702
613,rent abatement,4.056451612903226
614,sales agent,4.055555555555555
615,significant judgments,4.052631578947368
616,subsequent year,4.05252822778596
617,contracts,4.0474683544303796
618,unrestricted cash,4.046692607003891
619,cash charges,4.046692607003891
620,based awards,4.046649703138253
621,interest,4.045942116980369
622,funds,4.045454545454545
623,regulatory filings,4.045454545454545
624,regulatory approvals,4.045454545454545
625,intellectual property,4.044117647058823
626,allocated indirect,4.041666666666666
627,substantial completion,4.041501976284585
628,performance awards,4.040404040404041
629,net settlement,4.0390419161676645
630,producing enterobacteriaceae,4.038461538461538
631,strategic milestone,4.037037037037037
632,lease payments,4.032273419649657
633,derivative liability,4.031539888682746
634,advance payments,4.0295261669024045
635,directly observed,4.024630541871921
636,security interest,4.018387181507749
637,sales agreement,4.01193139448173
638,expenses,4.010954940057875
639,current contract,4.01039501039501
640,data inputs,4.008333333333333
641,comparable period,4.006993006993007
642,antibacterial drugs,4.0
643,acute pyelonephritis,4.0
644,exchange commission,4.0
645,necessarily indicative,4.0
646,accumulated deficit,4.0
647,adjustments,4.0
648,historical experience,4.0
649,readily apparent,4.0
650,rates,4.0
651,bank deposits,4.0
652,temporary decline,4.0
653,decisions,4.0
654,financially sound,4.0
655,arrangement,4.0
656,embedded call,4.0
657,orderly transaction,4.0
658,industry models,4.0
659,temporary impairments,4.0
660,national institute,4.0
661,infectious diseases,4.0
662,customary affirmative,4.0
663,voluntary prepayment,4.0
664,voluntarily prepay,4.0
665,customary representations,4.0
666,rsu activity,4.0
667,exchange act,4.0
668,similar expressions,4.0
669,nightmare bacteria,4.0
670,double blind,4.0
671,isolates,4.0
672,varying degrees,4.0
673,renal function,4.0
674,care,4.0
675,reviewed journal,4.0
676,innovation act,4.0
677,patent protection,4.0
678,multifaceted approach,4.0
679,antibacterial agents,4.0
680,national institutes,4.0
681,wellcome trust,4.0
682,explanatory paragraph,4.0
683,investigative sites,4.0
684,infrastructure,4.0
685,patent claims,4.0
686,competing technologies,4.0
687,practical expedients,4.0
688,actively traded,4.0
689,announce top,4.0
690,square feet,4.0
691,antibacterial treatments,4.0
692,bill,4.0
693,strategic relationship,4.0
694,microgenics corporation,4.0
695,efficacious doses,4.0
696,minimum quantity,4.0
697,cancellation clause,4.0
698,unused portion,4.0
699,freely tradable,4.0
700,freely tradeable,4.0
701,section,4.0
702,section,4.0
703,item,4.0
704,composite endpoint,4.0
705,microbiologically evaluable,4.0
706,rapidly address,4.0
707,enzyme essential,4.0
708,outer membrane,4.0
709,vestibular function,4.0
710,gates investment,3.9990898058252426
711,research funding,3.9957550030321407
712,exercise price,3.9945699123781315
713,costs,3.9944444444444445
714,funding pursuant,3.9934640522875817
715,expense relate,3.9904761904761905
716,lease amendment,3.990384615384616
717,carbapenem,3.990262901655307
718,related services,3.9870689655172415
719,development expenses,3.9799490417635983
720,marketable securities,3.9772727272727275
721,similar securities,3.9772727272727275
722,securities,3.9772727272727275
723,treasury securities,3.9772727272727275
724,volatility,3.9727272727272727
725,cre infections,3.970193252538487
726,inducement material,3.9701754385964914
727,incurred losses,3.9664634146341466
728,potential approval,3.966060606060606
729,revenue recognition,3.959448499594485
730,advance funds,3.9561688311688314
731,ionis,3.954887218045113
732,historical information,3.953488372093023
733,successfully developed,3.9523809523809526
734,subsequently modified,3.9444444444444446
735,development expense,3.943790849673203
736,expense,3.939784946236559
737,charitable default,3.9393939393939394
738,primarily accessed,3.9375
739,amendment,3.9340659340659343
740,immediately due,3.9338842975206614
741,pneumonia,3.9338842975206614
742,aminoglycoside products,3.9333333333333336
743,future period,3.932524921886624
744,term loan,3.9276771741560474
745,funding,3.9215686274509807
746,leasehold improvements,3.92
747,epic,3.92
748,full term,3.9144496609285344
749,lease,3.9134615384615383
750,niaid extended,3.9119047619047618
751,professional fees,3.909090909090909
752,quarterly report,3.9074074074074074
753,ourannual report,3.9074074074074074
754,anticipated results,3.9071566731141196
755,policy election,3.904761904761905
756,key assumptions,3.901595744680851
757,clinical development,3.8995664272309583
758,fair values,3.8887635379061374
759,mdr gram,3.886621315192744
760,preclinical activities,3.882978723404255
761,activities,3.882978723404255
762,limited activity,3.8823529411764706
763,customary events,3.88
764,term,3.8795912731289697
765,asu introduces,3.8777777777777778
766,asu simplifies,3.8777777777777778
767,study,3.875
768,prices,3.875
769,license fee,3.875
770,ongoing study,3.875
771,care study,3.875
772,study,3.875
773,expected term,3.8737089201877932
774,early exercise,3.8726833199033037
775,negative covenants,3.8716216216216215
776,primarily due,3.8713842975206614
777,control transactions,3.8708333333333336
778,purchase discounts,3.8700189753320684
779,amounts,3.8695652173913047
780,judgments,3.8684210526315788
781,amount,3.8560196560196562
782,credit risk,3.855769230769231
783,validation program,3.85
784,allotment option,3.848684210526316
785,decisions,3.836065573770492
786,costs,3.835907859078591
787,underwriting commissions,3.833613445378151
788,resource allocation,3.833333333333333
789,restrictions,3.833333333333333
790,initially capitalized,3.833333333333333
791,warrants,3.8318396008500417
792,warrants,3.8318396008500417
793,accounts payable,3.82905138339921
794,losses,3.8287037037037037
795,providing general,3.8275862068965516
796,categorized based,3.8244274809160306
797,based therapy,3.8244274809160306
798,disease,3.8235294117647056
799,year period,3.821425996683729
800,costs,3.818871925360475
801,potential effects,3.817171717171717
802,material impact,3.816842105263158
803,sponsored programs,3.8166666666666664
804,preclinical programs,3.8166666666666664
805,discovery efforts,3.816326530612245
806,disease control,3.8156862745098037
807,calendar year,3.8144329896907214
808,active markets,3.8125
809,derivative liabilities,3.812452253628724
810,diluted weighted,3.812265331664581
811,development authority,3.810457516339869
812,preclinical development,3.810457516339869
813,development efforts,3.810457516339869
814,development space,3.810457516339869
815,crystal biosciences,3.8095238095238093
816,security deposits,3.8085106382978724
817,cash,3.806186277889967
818,development costs,3.8049019607843135
819,liability,3.8010204081632653
820,government contracts,3.7974683544303796
821,customer contracts,3.7974683544303796
822,remaining life,3.7974481658692185
823,share data,3.7966814159292035
824,market&quot,3.796362023070098
825,letter agreement,3.7950855163455293
826,epic study,3.795
827,institutions,3.791666666666667
828,term liabilities,3.791355979011323
829,administrative support,3.7905660377358488
830,negative pledge,3.788288288288288
831,contract,3.786036036036036
832,unvested shares,3.784
833,conditions,3.7838680926916224
834,approval,3.7816450216450215
835,research team,3.7800687285223367
836,financial resources,3.775162337662338
837,company,3.768699654775604
838,company,3.768699654775604
839,estimated basis,3.7683760683760683
840,revenue,3.7653952914567697
841,security agreement,3.7648864772240467
842,existing contract,3.763308763308763
843,preparations,3.759493670886076
844,including ap,3.759493670886076
845,purchase price,3.756611450159837
846,clinical cure,3.755775577557756
847,payments,3.7551755175517556
848,expenses,3.7548573790822655
849,contract funding,3.75172231054584
850,funds,3.7513368983957216
851,lease liability,3.7501962323390896
852,laboratory supplies,3.75
853,explicit requirement,3.75
854,government agencies,3.75
855,landlord disburses,3.75
856,stockholders approval,3.743333333333333
857,collaborative agreements,3.742857142857143
858,full utilization,3.7407407407407405
859,manufacturing agreement,3.738984534578348
860,revenue,3.7372262773722627
861,additional disclosures,3.734246575342466
862,developing countries,3.7333333333333334
863,digit percentage,3.7264957264957266
864,worldwide license,3.7222222222222223
865,barda funding,3.7215686274509805
866,allowance&quot,3.721532091097308
867,identical assets,3.719178082191781
868,similar assets,3.719178082191781
869,000 shares,3.7143797468354434
870,partially offset,3.7142857142857144
871,share equal,3.7137866790870984
872,sales commissions,3.712698412698413
873,loan agreement,3.7103440928944282
874,fair statement,3.7084063950489945
875,prices,3.708333333333333
876,amounts,3.7074030552291424
877,future research,3.705600643415954
878,judgments,3.704486626402071
879,ongoing basis,3.7
880,regular basis,3.7
881,line basis,3.7
882,premiums,3.693548387096774
883,operations,3.6934643143544506
884,development activities,3.6934362397441247
885,track designation,3.6923076923076925
886,date,3.6913326481671804
887,product,3.6893687707641196
888,commercialized product,3.6893687707641196
889,term maturities,3.6888604353393086
890,fda pre,3.688311688311688
891,estimated cost,3.6874236874236876
892,periods,3.6854928017718716
893,management,3.6842105263157894
894,management evaluates,3.6842105263157894
895,management bases,3.6842105263157894
896,significant concentration,3.6842105263157894
897,management,3.6842105263157894
898,agreement,3.683648566198902
899,license agreement,3.6785980611483966
900,ionis pharmaceuticals,3.678571428571429
901,compensated ionis,3.678571428571429
902,clinical evaluation,3.677344205008736
903,transition method,3.676923076923077
904,cure period,3.6736596736596736
905,full exercise,3.672247590055809
906,periods,3.6708407871198565
907,plazomicin,3.6695804195804196
908,average number,3.669230769230769
909,differ materially,3.666666666666667
910,business strategy,3.666666666666667
911,business strategies,3.666666666666667
912,base rent,3.6635944700460827
913,research activities,3.663047451926592
914,agreement,3.662258191867351
915,grant agreement,3.662258191867351
916,additional collaboration,3.6592465753424657
917,indirect research,3.6550687285223367
918,purchase agreement,3.6499242260229487
919,defined period,3.6433566433566433
920,early adoption,3.6368286445012785
921,obligation,3.6363636363636367
922,prospectus,3.6333333333333337
923,inputs,3.6309523809523805
924,development programs,3.627124183006536
925,broad range,3.625
926,human services,3.625
927,collaboration partner,3.625
928,ongoing collaboration,3.625
929,contingent call,3.619047619047619
930,cost extension,3.619047619047619
931,accrued liabilities,3.6176470588235294
932,funding,3.615686274509804
933,company,3.614635697413845
934,licensed products,3.6
935,research programs,3.596735395189003
936,inducement plan,3.594235588972431
937,lease&quot,3.5873745819397995
938,initial fair,3.5845968712394702
939,observable inputs,3.583333333333333
940,unobservable inputs,3.583333333333333
941,inferiority margin,3.583333333333333
942,fully vested,3.583333333333333
943,inferiority,3.583333333333333
944,liabilities,3.5819327731092434
945,fair market,3.573712517497974
946,amounts,3.573268921095008
947,research institutions,3.5717353951890036
948,entity,3.571428571428571
949,entity,3.571428571428571
950,funding/development conditions,3.5681818181818183
951,subsequently exercised,3.566037735849057
952,rent,3.5659452837893015
953,sale securities,3.5655080213903743
954,entitled care,3.5652173913043477
955,safety profile,3.5652173913043477
956,common share,3.5643043667488756
957,crystal,3.564240790655885
958,final settlement,3.56
959,aggressive action,3.5555555555555554
960,full year,3.5551737304314623
961,guidance simplifies,3.55
962,authoritative guidance,3.55
963,implementation guidance,3.55
964,development organization,3.5437908496732025
965,market,3.5420293991722565
966,contract receivables,3.536036036036036
967,revenue contracts,3.5346946318026427
968,remaining option,3.5342902711323765
969,closing fee,3.532088122605364
970,fiscal years,3.531986531986532
971,5 million committed,3.529588963349414
972,completed contracts,3.524741081703107
973,estimated fair,3.5196396062822055
974,potential commitments,3.5155844155844154
975,loan,3.5148378191856455
976,capital resources,3.5090311986863707
977,additional option,3.5079307858687816
978,contract arrangements,3.503777971519907
979,customer concentration,3.5
980,effort,3.5
981,repurchase relating,3.5
982,sample size,3.5
983,strategic collaborations,3.5
984,based targets,3.4910941475826975
985,purchase contracts,3.491016741527154
986,entitled epic,3.4852173913043476
987,company,3.481177050797304
988,similar terms,3.4805194805194803
989,time period,3.4801112865628996
990,common shares,3.4766229508196718
991,atm&quot,3.473913043478261
992,public company,3.465979482408246
993,dtra,3.4620689655172416
994,applicable law,3.4545454545454546
995,expansion options,3.4543524416135885
996,tier,3.4512635379061374
997,costs,3.448989898989899
998,dividend yield,3.4444444444444446
999,present intention,3.4444444444444446
1000,continued progress,3.4444444444444446
1001,closing price,3.442373407890649
1002,cre,3.4339122755372387
1003,funding sources,3.43307757885763
1004,7 million related,3.4326415354240325
1005,2 million related,3.4326415354240325
1006,company,3.429228998849252
1007,consulting costs,3.429227053140097
1008,colistin therapy,3.428571428571429
1009,niaid modified,3.427777777777778
1010,potentially enter,3.424242424242424
1011,million payment,3.4235137463773793
1012,hovione,3.4230769230769234
1013,potential commercialization,3.42174688057041
1014,produce plazomicin,3.4195804195804196
1015,permit plazomicin,3.4195804195804196
1016,plazomicin,3.4195804195804196
1017,closed enrollment,3.4107142857142856
1018,company,3.4066959763162297
1019,company,3.4065017261219794
1020,lactamase inhibitor,3.4
1021,lowest level,3.397590361445783
1022,2 valuations,3.397590361445783
1023,performance conditions,3.3863636363636362
1024,funded primarily,3.384868421052632
1025,company funds,3.3837744533947065
1026,asu clarifies,3.3777777777777778
1027,devoted substantially,3.375
1028,declared effective,3.375
1029,exercises,3.3711340206185567
1030,collaboration agreements,3.367857142857143
1031,company,3.366488922024668
1032,fda&quot,3.362224731789949
1033,personnel expenses,3.361799217731421
1034,actual results,3.3617021276595747
1035,historical results,3.3617021276595747
1036,line results,3.3617021276595747
1037,report,3.351851851851852
1038,remaining shares,3.3446060606060604
1039,consulting fees,3.3438735177865615
1040,company,3.338319907940161
1041,company reviews,3.338319907940161
1042,company,3.338319907940161
1043,company,3.338319907940161
1044,company measures,3.338319907940161
1045,company elects,3.338319907940161
1046,company,3.338319907940161
1047,company,3.338319907940161
1048,company,3.338319907940161
1049,company,3.338319907940161
1050,company,3.338319907940161
1051,plazomicin program,3.336247086247086
1052,commenced operations,3.3313953488372094
1053,operations,3.3313953488372094
1054,advance plazomicin,3.3302947052947056
1055,issuance costs,3.3277777777777775
1056,shares,3.3256666666666668
1057,licensing arrangements,3.324884792626728
1058,increased research,3.3239283776451436
1059,periods,3.322938689217759
1060,research contract,3.3161047645583728
1061,employee time,3.315223542727787
1062,underwriters,3.3125
1063,control principle,3.3083333333333336
1064,5 years,3.306973848069738
1065,hovione limited,3.3054298642533935
1066,risk factors,3.291666666666667
1067,services,3.291666666666667
1068,niaid contracts,3.280801687763713
1069,contract revenue,3.273262313408299
1070,1 prices,3.272590361445783
1071,potentially subject,3.267379679144385
1072,scholes&quot,3.2648221343873516
1073,future issuance,3.2588652482269502
1074,safety,3.253529079616036
1075,terms,3.2532467532467533
1076,acceptable terms,3.2532467532467533
1077,cowen,3.25
1078,twelve months,3.25
1079,valuation hierarchy,3.2486631016042784
1080,multiple targets,3.238095238095238
1081,contingent liabilities,3.2366946778711485
1082,commercialization milestones,3.236519607843137
1083,required quantity,3.235955056179775
1084,exclusive license,3.2222222222222223
1085,material terms,3.2173615857826388
1086,employee share,3.2137866790870984
1087,patients,3.2133333333333334
1088,amortization expense,3.2133333333333334
1089,security deposit,3.2085106382978723
1090,warrant liability,3.207868714496108
1091,prepared assuming,3.2
1092,company,3.1954627650830183
1093,qidp designation,3.1923076923076925
1094,information,3.1894434282727984
1095,evaluating plazomicin,3.1888111888111887
1096,plazomicin,3.1790740904664956
1097,part,3.178571428571429
1098,employee directors,3.1754385964912277
1099,rsus&quot,3.1739130434782608
1100,expected time,3.1731182795698922
1101,company,3.1716532412734946
1102,development plan,3.171359771978967
1103,employees,3.169811320754717
1104,month libor,3.161290322580645
1105,date,3.159119763013119
1106,niaid&quot,3.157246376811594
1107,option,3.1475972540045767
1108,option,3.1475972540045767
1109,option 3&quot,3.1475972540045767
1110,noncash consideration,3.142857142857143
1111,entity conditions,3.1396103896103895
1112,evergreen increase,3.1372549019607843
1113,increase significantly,3.1372549019607843
1114,5 million remaining,3.1311786305128515
1115,2014 plan,3.130133024869867
1116,2003 plan,3.130133024869867
1117,actual timing,3.119047619047619
1118,assets,3.116613979627678
1119,fourth quarter,3.111111111111111
1120,amounts,3.10552027357108
1121,additional $20 million,3.1048191452492566
1122,stockholders,3.1045454545454545
1123,llc,3.1
1124,company,3.093036889072237
1125,maturity date,3.089601046435579
1126,developing plazomicin,3.086247086247086
1127,change,3.0837713011626056
1128,isos&quot,3.073913043478261
1129,scope improvements,3.0738461538461537
1130,lease approximately 47,3.073838896952105
1131,top,3.0727272727272728
1132,barda,3.0719200887902334
1133,performance,3.0681818181818183
1134,company,3.065592635212888
1135,company,3.065592635212888
1136,549 shares,3.0617777777777775
1137,plazomicin,3.055944055944056
1138,successful commercialization,3.049019607843137
1139,increased size,3.043859649122807
1140,barda contract,3.0419183889772126
1141,measurement date,3.0365707434052758
1142,contract modifications,3.036036036036036
1143,2014 plan&quot,3.0348152991173585
1144,2003 plan&quot,3.0348152991173585
1145,earlier stages,3.0285714285714285
1146,2003 plan,3.0275689223057647
1147,applicable conditions,3.0227272727272725
1148,company,3.0173322536191733
1149,3 liabilities,3.0152374202693126
1150,maturities,3.015151515151515
1151,record research,3.0108379592915675
1152,contract option,3.0097202465623516
1153,anticipate general,3.0061576354679804
1154,estimates,3.0
1155,warrant liabilities,2.988781079442086
1156,level,2.9809236947791167
1157,development employees,2.9802688370945862
1158,generally straight,2.9728506787330318
1159,patients,2.9728270042194094
1160,warrants,2.9674975898636555
1161,operations,2.9563953488372094
1162,successful completion,2.9545454545454546
1163,amortized cost,2.9523809523809526
1164,contingent put,2.9523809523809526
1165,shares,2.9506666666666668
1166,hovione depending,2.9230769230769234
1167,lender,2.9213836477987423
1168,support plazomicin,2.9101464573162685
1169,date,2.9045009479780797
1170,fasb,2.8823529411764706
1171,reasonable assurance,2.833333333333333
1172,closing date,2.8325477548995286
1173,effective date,2.8282374100719423
1174,condensed,2.8076923076923075
1175,treat multi,2.8
1176,critical,2.8
1177,liabilities,2.7924043403769274
1178,generally derived,2.788235294117647
1179,directors,2.787878787878788
1180,issuance date,2.7865707434052758
1181,million grant,2.776454922847967
1182,fully recorded,2.758090614886731
1183,extent,2.735955056179775
1184,plazomicin treatment,2.730691530691531
1185,short maturities,2.7264191207853177
1186,company,2.7229352925555457
1187,lead,2.7
1188,money,2.7
1189,level,2.6833046471600692
1190,shares,2.668615384615385
1191,advanced,2.64
1192,black scholes,2.6363636363636362
1193,million settlement,2.630572569906791
1194,accounting,2.5961538461538463
1195,company,2.588319907940161
1196,external,2.5789473684210527
1197,company,2.570878047475045
1198,retrospective,2.5555555555555554
1199,collectability,2.5357142857142856
1200,offerings,2.533333333333333
1201,restricted,2.5208333333333335
1202,39 patients,2.5133333333333336
1203,company,2.513077189493559
1204,company,2.5022543341696695
1205,consolidation achaogen,2.5
1206,aggregate,2.5
1207,organizations,2.5
1208,discover,2.5
1209,net,2.4790419161676644
1210,current,2.4743589743589745
1211,rate,2.473684210526316
1212,model,2.4722222222222223
1213,effective april,2.465909090909091
1214,shares,2.460470588235294
1215,committed,2.459016393442623
1216,issued,2.430379746835443
1217,mutually,2.4285714285714284
1218,endpoints,2.4285714285714284
1219,registration,2.4166666666666665
1220,annual,2.411764705882353
1221,equipment depreciation,2.393518518518518
1222,530 patients,2.3737106918238995
1223,units,2.3636363636363638
1224,related,2.3620689655172415
1225,000 related,2.3620689655172415
1226,proceeds,2.3592233009708736
1227,statements,2.355421686746988
1228,million shares,2.354572569906791
1229,payment,2.3529411764705883
1230,equal,2.3421052631578947
1231,compensation,2.3392857142857144
1232,recorded approximately $4,2.335134640043964
1233,recorded approximately $5,2.335134640043964
1234,requirements,2.3333333333333335
1235,relates,2.3333333333333335
1236,marketing,2.2857142857142856
1237,granted,2.276315789473684
1238,party,2.272727272727273
1239,statement,2.257142857142857
1240,stock,2.2553699284009547
1241,measurements,2.25
1242,million subject,2.247043158142085
1243,loans,2.2325581395348837
1244,approximately $15 million,2.230949928397357
1245,seek,2.230769230769231
1246,awards,2.2222222222222223
1247,total,2.2222222222222223
1248,technology,2.2222222222222223
1249,funding,2.215686274509804
1250,interest,2.2098765432098766
1251,periods,2.2093023255813953
1252,million increase,2.207827471867575
1253,equity,2.203125
1254,obtain,2.2
1255,favorable,2.2
1256,significant,2.1842105263157894
1257,offering,2.1839080459770117
1258,trial,2.1739130434782608
1259,term,2.1737089201877935
1260,expenses,2.169491525423729
1261,2016 notes,2.1666666666666665
1262,allocated,2.1666666666666665
1263,incentive,2.1666666666666665
1264,materials,2.1666666666666665
1265,2017 notes,2.1666666666666665
1266,income,2.1538461538461537
1267,fee,2.1527777777777777
1268,provide,2.142857142857143
1269,debt,2.1379310344827585
1270,expense,2.1333333333333333
1271,initial $15,2.1333333333333333
1272,initial,2.1333333333333333
1273,public,2.127659574468085
1274,losses,2.125
1275,loss,2.125
1276,enrollment,2.125
1277,market,2.122448979591837
1278,options,2.121019108280255
1279,payments,2.118811881188119
1280,include,2.111111111111111
1281,mdr,2.111111111111111
1282,antibiotics,2.111111111111111
1283,intended,2.1
1284,approval,2.0933333333333333
1285,principal,2.0925925925925926
1286,gain,2.090909090909091
1287,defaults,2.090909090909091
1288,clinical,2.089108910891089
1289,work,2.088235294117647
1290,impact,2.08
1291,previously,2.076923076923077
1292,signing,2.0714285714285716
1293,estimated,2.0683760683760686
1294,accounts,2.0681818181818183
1295,designed,2.066666666666667
1296,complete,2.066666666666667
1297,price,2.063063063063063
1298,active,2.0625
1299,sales,2.0555555555555554
1300,requires,2.0476190476190474
1301,allowance,2.0476190476190474
1302,cash,2.046692607003891
1303,product,2.046511627906977
1304,funds,2.0454545454545454
1305,regulatory,2.0454545454545454
1306,held,2.0416666666666665
1307,enterobacteriaceae,2.0384615384615383
1308,milestone,2.037037037037037
1309,additional $60,2.0342465753424657
1310,additional $10,2.0342465753424657
1311,4%,2.0342465753424657
1312,additional 500,2.0342465753424657
1313,additional,2.0342465753424657
1314,additional $15,2.0342465753424657
1315,additional $20,2.0342465753424657
1316,additional 975,2.0342465753424657
1317,additional 450,2.0342465753424657
1318,additional 750,2.0342465753424657
1319,additional 51,2.0342465753424657
1320,additional $0,2.0342465753424657
1321,received,2.028169014084507
1322,amount,2.018181818181818
1323,period,2.006993006993007
1324,adjustments,2.0
1325,normal,2.0
1326,balances,2.0
1327,government,2.0
1328,exchange,2.0
1329,account,2.0
1330,observable,2.0
1331,developments,2.0
1332,line,2.0
1333,act,2.0
1334,incentives,2.0
1335,preclinical,2.0
1336,litigation,2.0
1337,care,2.0
1338,launch,2.0
1339,carlo,2.0
1340,obligation,2.0
1341,day,2.0
1342,costs,1.9944444444444445
1343,securities,1.9772727272727273
1344,investments,1.9753086419753085
1345,arrangements,1.967741935483871
1346,measured,1.9642857142857142
1347,agreement,1.9563758389261745
1348,valuation,1.9545454545454546
1349,information,1.9534883720930232
1350,modified,1.9444444444444444
1351,early,1.9411764705882353
1352,caused,1.9411764705882353
1353,transactions,1.9375
1354,overhead,1.9375
1355,primarily,1.9375
1356,due,1.9338842975206612
1357,validation,1.9333333333333333
1358,exercise,1.9315068493150684
1359,future,1.925531914893617
1360,expenditures,1.9230769230769231
1361,improvements,1.92
1362,epic,1.92
1363,program,1.9166666666666667
1364,lease,1.9134615384615385
1365,advance,1.9107142857142858
1366,fees,1.9090909090909092
1367,report,1.9074074074074074
1368,conduct,1.903225806451613
1369,antibiotic,1.8888888888888888
1370,assay,1.8888888888888888
1371,activities,1.8829787234042554
1372,limited,1.8823529411764706
1373,disease,1.8823529411764706
1374,events,1.88
1375,asu,1.8777777777777778
1376,prices,1.875
1377,study,1.875
1378,indirect,1.875
1379,potential $1,1.8727272727272728
1380,potential,1.8727272727272728
1381,amounts,1.8695652173913044
1382,judgments,1.868421052631579
1383,provided,1.858974358974359
1384,relate,1.8571428571428572
1385,base,1.8571428571428572
1386,adopted,1.8571428571428572
1387,award,1.8461538461538463
1388,investment,1.84375
1389,employee,1.8421052631578947
1390,incurred,1.8414634146341464
1391,incurred $1,1.8414634146341464
1392,letter,1.8387096774193548
1393,carrying,1.837837837837838
1394,liability,1.836734693877551
1395,make,1.8360655737704918
1396,executed,1.8333333333333333
1397,general,1.8275862068965518
1398,based,1.8244274809160306
1399,identified,1.8235294117647058
1400,performance,1.8181818181818181
1401,programs,1.8166666666666667
1402,discovery,1.816326530612245
1403,year,1.8144329896907216
1404,development,1.8104575163398693
1405,crystal,1.8095238095238095
1406,security,1.8085106382978724
1407,rent,1.8064516129032258
1408,atm,1.8
1409,expires,1.8
1410,contractually,1.8
1411,contracts,1.7974683544303798
1412,property,1.7941176470588236
1413,institutions,1.7916666666666667
1414,manufacturing,1.7826086956521738
1415,research,1.7800687285223367
1416,70 research,1.7800687285223367
1417,pursuant,1.7777777777777777
1418,considered,1.7777777777777777
1419,gram,1.7755102040816326
1420,acceptable,1.7727272727272727
1421,evaluating,1.7692307692307692
1422,expire,1.7692307692307692
1423,payable,1.7608695652173914
1424,including,1.759493670886076
1425,including $20,1.759493670886076
1426,including $0,1.759493670886076
1427,including $1,1.759493670886076
1428,including $2,1.759493670886076
1429,agreed,1.7547169811320755
1430,loan,1.753968253968254
1431,december31,1.75
1432,agencies,1.75
1433,evidence,1.75
1434,markets,1.75
1435,december31,1.75
1436,covenants,1.75
1437,laboratory,1.75
1438,agreements,1.7428571428571429
1439,pay $1,1.7428571428571429
1440,pay,1.7428571428571429
1441,full,1.7407407407407407
1442,revenue,1.7372262773722629
1443,life,1.736842105263158
1444,material,1.736842105263158
1445,organization,1.7333333333333334
1446,standard,1.7333333333333334
1447,classification,1.7272727272727273
1448,completed,1.7272727272727273
1449,reached,1.7272727272727273
1450,license,1.7222222222222223
1451,assets,1.7191780821917808
1452,offset,1.7142857142857142
1453,observed,1.7142857142857142
1454,2015 included,1.710144927536232
1455,included,1.710144927536232
1456,included 900,1.710144927536232
1457,000 included,1.710144927536232
1458,2016 included,1.710144927536232
1459,grant,1.7058823529411764
1460,000 grant,1.7058823529411764
1461,reported,1.7037037037037037
1462,basis,1.7
1463,expected,1.7
1464,efficacy,1.7
1465,disclosures,1.7
1466,adoption,1.6956521739130435
1467,purchase,1.6935483870967742
1468,purchase,1.6935483870967742
1469,purchase,1.6935483870967742
1470,purchase,1.6935483870967742
1471,purchase 78,1.6935483870967742
1472,designation,1.6923076923076923
1473,fda,1.6883116883116882
1474,milestones,1.6875
1475,management,1.6842105263157894
1476,entered,1.6790123456790123
1477,ionis,1.6785714285714286
1478,cre,1.6744186046511629
1479,&quot,1.673913043478261
1480,developing,1.6666666666666667
1481,business,1.6666666666666667
1482,disclosure,1.6666666666666667
1483,leases,1.6666666666666667
1484,vesting,1.6666666666666667
1485,vest,1.6666666666666667
1486,health,1.6666666666666667
1487,differ,1.6666666666666667
1488,pledge,1.6666666666666667
1489,factors,1.6666666666666667
1490,apply,1.6666666666666667
1491,targets,1.6666666666666667
1492,developed,1.6666666666666667
1493,cure,1.6666666666666667
1494,unmet,1.6666666666666667
1495,commissions,1.6571428571428573
1496,stockholders,1.65
1497,identifying,1.6428571428571428
1498,commitments,1.6428571428571428
1499,commercialized,1.6428571428571428
1500,includes 900,1.6363636363636365
1501,maturity,1.6363636363636365
1502,defined,1.6363636363636365
1503,patient,1.6363636363636365
1504,includes,1.6363636363636365
1505,made,1.6363636363636365
1506,2016 includes $25,1.6363636363636365
1507,2017 includes $0,1.6363636363636365
1508,services,1.625
1509,risk,1.625
1510,collaboration,1.625
1511,comparison,1.625
1512,cost,1.619047619047619
1513,contingent,1.619047619047619
1514,liabilities,1.6176470588235294
1515,percentage,1.6153846153846154
1516,performed,1.6111111111111112
1517,products,1.6
1518,stages,1.6
1519,transition,1.6
1520,scholes,1.5909090909090908
1521,sale,1.588235294117647
1522,evaluation,1.588235294117647
1523,generally,1.588235294117647
1524,prepaid,1.5853658536585367
1525,inputs,1.5833333333333333
1526,measurement,1.5833333333333333
1527,inferiority,1.5833333333333333
1528,fully,1.5833333333333333
1529,entity,1.5714285714285714
1530,intent,1.5714285714285714
1531,primary,1.5714285714285714
1532,multiple,1.5714285714285714
1533,election,1.5714285714285714
1534,conditions,1.5681818181818181
1535,exercised,1.5660377358490567
1536,safety,1.565217391304348
1537,entitled,1.565217391304348
1538,settlement,1.56
1539,action,1.5555555555555556
1540,guidance,1.55
1541,commercialization,1.5490196078431373
1542,agency,1.5454545454545454
1543,2016 increased,1.543859649122807
1544,increased,1.543859649122807
1545,2017 increased,1.543859649122807
1546,contract,1.5360360360360361
1547,covering,1.5333333333333334
1548,capitalized,1.5333333333333334
1549,maturities,1.5151515151515151
1550,barda,1.5058823529411764
1551,assurance,1.5
1552,concentration,1.5
1553,met,1.5
1554,effort,1.5
1555,paid,1.5
1556,exclusive,1.5
1557,borrowings,1.5
1558,greater,1.5
1559,rsus,1.5
1560,repurchase,1.5
1561,extent,1.5
1562,425 rsus,1.5
1563,successful,1.5
1564,qidp,1.5
1565,collaborations,1.5
1566,size,1.5
1567,clarifies,1.5
1568,175 rsus,1.5
1569,modifications,1.5
1570,depending,1.5
1571,cohort,1.5
1572,cohort,1.5
1573,support,1.490566037735849
1574,default,1.4848484848484849
1575,beginning,1.4848484848484849
1576,niaid,1.4833333333333334
1577,terms,1.4805194805194806
1578,presented,1.4761904761904763
1579,option,1.4736842105263157
1580,option,1.4736842105263157
1581,option,1.4736842105263157
1582,option,1.4736842105263157
1583,time,1.4731182795698925
1584,resulted,1.4615384615384615
1585,completion,1.4545454545454546
1586,applicable,1.4545454545454546
1587,approved,1.4545454545454546
1588,involved,1.4545454545454546
1589,date,1.4532374100719425
1590,fair,1.4512635379061372
1591,funded,1.4473684210526316
1592,return,1.4444444444444444
1593,present,1.4444444444444444
1594,yield,1.4444444444444444
1595,progress,1.4444444444444444
1596,consulting,1.434782608695652
1597,exercisable,1.434782608695652
1598,resources,1.4285714285714286
1599,earlier,1.4285714285714286
1600,colistin,1.4285714285714286
1601,hovione,1.4230769230769231
1602,plazomicin,1.4195804195804196
1603,warrants,1.4014598540145986
1604,multi,1.4
1605,number,1.4
1606,awarded,1.4
1607,isos,1.4
1608,lactamase,1.4
1609,treat,1.4
1610,deposit,1.4
1611,level,1.3975903614457832
1612,level,1.3975903614457832
1613,level,1.3975903614457832
1614,level,1.3975903614457832
1615,recognized,1.3974358974358974
1616,recognized $0,1.3974358974358974
1617,sell,1.3846153846153846
1618,straight,1.3846153846153846
1619,filed,1.3846153846153846
1620,sell 407,1.3846153846153846
1621,closing,1.3793103448275863
1622,principle,1.375
1623,effective,1.375
1624,substantially,1.375
1625,range,1.375
1626,change,1.3736263736263736
1627,share,1.3716814159292035
1628,warrant,1.3711340206185567
1629,results,1.3617021276595744
1630,2014 plan,1.3609022556390977
1631,2003 plan,1.3609022556390977
1632,plan,1.3609022556390977
1633,68 plan,1.3609022556390977
1634,licensing,1.3571428571428572
1635,gaap,1.3548387096774193
1636,company,1.338319907940161
1637,consolidation,1.3333333333333333
1638,issuance,1.3333333333333333
1639,reasonable,1.3333333333333333
1640,fixed,1.3333333333333333
1641,put,1.3333333333333333
1642,dilutive,1.3333333333333333
1643,amortized,1.3333333333333333
1644,directors,1.3333333333333333
1645,represent,1.3333333333333333
1646,allowances,1.3333333333333333
1647,enter,1.3333333333333333
1648,expansion,1.3333333333333333
1649,case,1.3333333333333333
1650,lpxc,1.3333333333333333
1651,operations,1.3313953488372092
1652,underwriters,1.3125
1653,treatment,1.3111111111111111
1654,enrolled,1.3
1655,hierarchy,1.2941176470588236
1656,collectability,1.2857142857142858
1657,input,1.2857142857142858
1658,closed,1.2857142857142858
1659,shares,1.284
1660,000 shares,1.284
1661,894 shares,1.284
1662,402 shares,1.284
1663,838 shares,1.284
1664,808 shares,1.284
1665,952 shares,1.284
1666,750 shares,1.284
1667,996 shares,1.284
1668,999 shares,1.284
1669,520 shares,1.284
1670,453 shares,1.284
1671,363 shares,1.284
1672,527 shares,1.284
1673,950 shares,1.284
1674,250 shares,1.284
1675,549 shares,1.284
1676,331 shares,1.284
1677,585 shares,1.284
1678,522 shares,1.284
1679,190 shares,1.284
1680,facilities,1.2777777777777777
1681,assumptions,1.2765957446808511
1682,years,1.2727272727272727
1683,10 years,1.2727272727272727
1684,0 years,1.2727272727272727
1685,25 years,1.2727272727272727
1686,7 years,1.2727272727272727
1687,decrease,1.2666666666666666
1688,cowen,1.25
1689,months,1.25
1690,classified,1.25
1691,assessing,1.25
1692,24 months,1.25
1693,meropenem,1.25
1694,supersede,1.25
1695,end,1.25
1696,required,1.2359550561797752
1697,sold 197,1.2325581395348837
1698,sold,1.2325581395348837
1699,sold 6,1.2325581395348837
1700,sold 267,1.2325581395348837
1701,sold 7,1.2325581395348837
1702,sold 1,1.2325581395348837
1703,record,1.2307692307692308
1704,nda,1.2222222222222223
1705,nonclinical,1.2222222222222223
1706,sources,1.2173913043478262
1707,patients,1.2133333333333334
1708,609 patients,1.2133333333333334
1709,69 patients,1.2133333333333334
1710,30 patients,1.2133333333333334
1711,short,1.2112676056338028
1712,deducting,1.2105263157894737
1713,equipment,1.2083333333333333
1714,prepared,1.2
1715,derived,1.2
1716,personnel,1.1923076923076923
1717,develop,1.1904761904761905
1718,depreciation,1.1851851851851851
1719,part,1.1785714285714286
1720,anticipate,1.1785714285714286
1721,subject,1.1764705882352942
1722,recorded,1.174757281553398
1723,recorded $1,1.174757281553398
1724,employees,1.169811320754717
1725,19 employees,1.169811320754717
1726,46 employees,1.169811320754717
1727,22 employees,1.169811320754717
1728,achaogen,1.1666666666666667
1729,earnings,1.1666666666666667
1730,lender,1.1666666666666667
1731,lender,1.1666666666666667
1732,consultant,1.1666666666666667
1733,68 achaogen,1.1666666666666667
1734,70 achaogen,1.1666666666666667
1735,office,1.1666666666666667
1736,71 achaogen,1.1666666666666667
1737,estimates,1.1639344262295082
1738,month,1.1612903225806452
1739,approximately $73,1.1603773584905661
1740,approximately $375,1.1603773584905661
1741,approximately $356,1.1603773584905661
1742,approximately $7,1.1603773584905661
1743,approximately $6,1.1603773584905661
1744,approximately $148,1.1603773584905661
1745,approximately $3,1.1603773584905661
1746,approximately $4,1.1603773584905661
1747,approximately $2,1.1603773584905661
1748,approximately 3,1.1603773584905661
1749,approximately $1,1.1603773584905661
1750,approximately $10,1.1603773584905661
1751,approximately $602,1.1603773584905661
1752,approximately $28,1.1603773584905661
1753,scope,1.1538461538461537
1754,consideration,1.1428571428571428
1755,increase,1.1372549019607843
1756,continue,1.131578947368421
1757,timing,1.119047619047619
1758,determined,1.1136363636363635
1759,quarter,1.1111111111111112
1760,weighted,1.1063829787234043
1761,llc,1.1
1762,dtra,1.1
1763,scape,1.1
1764,asset,1.0952380952380953
1765,april,1.0909090909090908
1766,april,1.0909090909090908
1767,assessment,1.0909090909090908
1768,april,1.0909090909090908
1769,april,1.0909090909090908
1770,april,1.0909090909090908
1771,april,1.0909090909090908
1772,page,1.0808080808080809
1773,page,1.0808080808080809
1774,page,1.0808080808080809
1775,page,1.0808080808080809
1776,page,1.0808080808080809
1777,page,1.0808080808080809
1778,page,1.0808080808080809
1779,page,1.0808080808080809
1780,page,1.0808080808080809
1781,page,1.0808080808080809
1782,page,1.0808080808080809
1783,page,1.0808080808080809
1784,page,1.0808080808080809
1785,page,1.0808080808080809
1786,page,1.0808080808080809
1787,page,1.0808080808080809
1788,page,1.0808080808080809
1789,page,1.0808080808080809
1790,page,1.0808080808080809
1791,page,1.0808080808080809
1792,page,1.0808080808080809
1793,page,1.0808080808080809
1794,page,1.0808080808080809
1795,page,1.0808080808080809
1796,page,1.0808080808080809
1797,page,1.0808080808080809
1798,amortization,1.08
1799,expect,1.0727272727272728
1800,0 million,1.070572569906791
1801,4 million,1.070572569906791
1802,3 million,1.070572569906791
1803,9 million,1.070572569906791
1804,5 million,1.070572569906791
1805,2 million,1.070572569906791
1806,6 million,1.070572569906791
1807,8 million,1.070572569906791
1808,$50 million,1.070572569906791
1809,1 million,1.070572569906791
1810,$150 million,1.070572569906791
1811,7 million,1.070572569906791
1812,fund,1.0606060606060606
1813,evaluate,1.0476190476190477
1814,black,1.0454545454545454
1815,item1,1.0
1816,thousands,1.0
1817,unaudited,1.0
1818,march 31,1.0
1819,presentation,1.0
1820,cuti,1.0
1821,serve,1.0
1822,addition,1.0
1823,completing,1.0
1824,incorporated,1.0
1825,delaware,1.0
1826,accordance,1.0
1827,sec,1.0
1828,permitted,1.0
1829,rules,1.0
1830,footnotes,1.0
1831,omitted,1.0
1832,opinion,1.0
1833,reflect,1.0
1834,consisting,1.0
1835,eliminated,1.0
1836,read,1.0
1837,conjunction,1.0
1838,form 10,1.0
1839,form,1.0
1840,march 2014,1.0
1841,ipo,1.0
1842,connection,1.0
1843,converted,1.0
1844,inception,1.0
1845,result,1.0
1846,sufficient,1.0
1847,raising,1.0
1848,unable,1.0
1849,meet,1.0
1850,forced,1.0
1851,delay,1.0
1852,reduce,1.0
1853,limit,1.0
1854,cease,1.0
1855,lack,1.0
1856,resultant,1.0
1857,order,1.0
1858,ability,1.0
1859,concern,1.0
1860,contemplates,1.0
1861,realization,1.0
1862,recoverability,1.0
1863,reclassification,1.0
1864,summary,1.0
1865,preparation,1.0
1866,conformity,1.0
1867,affect,1.0
1868,revenues,1.0
1869,believed,1.0
1870,circumstances,1.0
1871,carried,1.0
1872,december,1.0
1873,acquisition,1.0
1874,excluded,1.0
1875,component,1.0
1876,accretion,1.0
1877,experienced,1.0
1878,long,1.0
1879,consists,1.0
1880,serves,1.0
1881,collateral,1.0
1882,april14,1.0
1883,components,1.0
1884,enterprise,1.0
1885,deposited,1.0
1886,checking,1.0
1887,respect,1.0
1888,types,1.0
1889,type,1.0
1890,issuer,1.0
1891,exposed,1.0
1892,event,1.0
1893,issuing,1.0
1894,determinable,1.0
1895,iii,1.0
1896,delivered,1.0
1897,assured,1.0
1898,rendered,1.0
1899,parties,1.0
1900,deemed,1.0
1901,reduction,1.0
1902,refundable,1.0
1903,expensed,1.0
1904,payroll,1.0
1905,utilities,1.0
1906,behalf,1.0
1907,expended,1.0
1908,estimate,1.0
1909,adjust,1.0
1910,accrual,1.0
1911,receipt,1.0
1912,goods,1.0
1913,customers,1.0
1914,topic,1.0
1915,depict,1.0
1916,transfer,1.0
1917,reflects,1.0
1918,nature,1.0
1919,uncertainty,1.0
1920,fulfill,1.0
1921,december,1.0
1922,august 2014,1.0
1923,uncertainties,1.0
1924,topic,1.0
1925,assess,1.0
1926,entities,1.0
1927,december15,1.0
1928,november 2015,1.0
1929,topic,1.0
1930,require,1.0
1931,noncurrent,1.0
1932,february 2016,1.0
1933,lessee,1.0
1934,recognize,1.0
1935,calculated,1.0
1936,march,1.0
1937,derivatives,1.0
1938,hedging,1.0
1939,topic,1.0
1940,accelerate,1.0
1941,amendments,1.0
1942,update,1.0
1943,applied,1.0
1944,topic,1.0
1945,forfeitures,1.0
1946,occur,1.0
1947,computed,1.0
1948,dividing,1.0
1949,purposes,1.0
1950,calculation,1.0
1951,effect,1.0
1952,computations,1.0
1953,listed,1.0
1954,judgment,1.0
1955,measure,1.0
1956,corroborated,1.0
1957,supported,1.0
1958,significance,1.0
1959,days,1.0
1960,cases,1.0
1961,transparency,1.0
1962,recovery,1.0
1963,recover,1.0
1964,note 7,1.0
1965,food,1.0
1966,obtained,1.0
1967,august,1.0
1968,specifically,1.0
1969,probability,1.0
1970,sensitive,1.0
1971,january 2006,1.0
1972,series,1.0
1973,sublicensees,1.0
1974,achievement,1.0
1975,august 2010,1.0
1976,countermeasure,1.0
1977,biothreats,1.0
1978,september,1.0
1979,november,1.0
1980,division,1.0
1981,department,1.0
1982,defense,1.0
1983,terminated,1.0
1984,convenience,1.0
1985,antibacterials,1.0
1986,termination,1.0
1987,claim,1.0
1988,allergy,1.0
1989,july,1.0
1990,june,1.0
1991,january 2016,1.0
1992,added,1.0
1993,february 2018,1.0
1994,july,1.0
1995,july,1.0
1996,august 15,1.0
1997,annum,1.0
1998,february 2017,1.0
1999,march,1.0
2000,grants,1.0
2001,august 2017,1.0
2002,september,1.0
2003,occurrence,1.0
2004,declare,1.0
2005,actions,1.0
2006,set,1.0
2007,obligated,1.0
2008,earliest,1.0
2009,acceleration,1.0
2010,warranties,1.0
2011,entitle,1.0
2012,indebtedness,1.0
2013,8%,1.0
2014,accretes,1.0
2015,issue,1.0
2016,september,1.0
2017,february 2014,1.0
2018,march,1.0
2019,january 1,1.0
2020,board,1.0
2021,provisions,1.0
2022,december,1.0
2023,comply,1.0
2024,nasdaq,1.0
2025,rule,1.0
2026,person,1.0
2027,director,1.0
2028,employment,1.0
2029,individual,1.0
2030,entering,1.0
2031,authorized,1.0
2032,resulting,1.0
2033,march 17,1.0
2034,espp,1.0
2035,march11,1.0
2036,amended,1.0
2037,granting,1.0
2038,consultants,1.0
2039,discretion,1.0
2040,january 2014,1.0
2041,continues,1.0
2042,govern,1.0
2043,march21,1.0
2044,transferred,1.0
2045,forfeited,1.0
2046,monte,1.0
2047,output,1.0
2048,obligates,1.0
2049,reservation,1.0
2050,procurement,1.0
2051,impairment,1.0
2052,recoverable,1.0
2053,discussion,1.0
2054,analysis,1.0
2055,form10,1.0
2056,forward,1.0
2057,meaning,1.0
2058,section27a,1.0
2059,section21e,1.0
2060,words,1.0
2061,intend,1.0
2062,variations,1.0
2063,risks,1.0
2064,item1a,1.0
2065,views,1.0
2066,elect,1.0
2067,point,1.0
2068,rely,1.0
2069,representing,1.0
2070,overview,1.0
2071,centers,1.0
2072,urgent,1.0
2073,randomized,1.0
2074,submit,1.0
2075,half,1.0
2076,enroll,1.0
2077,esbl,1.0
2078,morbidities,1.0
2079,peer,1.0
2080,microbiology,1.0
2081,dosing,1.0
2082,inform,1.0
2083,created,1.0
2084,functions,1.0
2085,focused,1.0
2086,mechanisms,1.0
2087,taking,1.0
2088,identify,1.0
2089,goal,1.0
2090,file,1.0
2091,investigational,1.0
2092,ind,1.0
2093,financed,1.0
2094,issuances,1.0
2095,nih,1.0
2096,historically,1.0
2097,pipeline,1.0
2098,march17,1.0
2099,profitable,1.0
2100,commencement,1.0
2101,prepare,1.0
2102,proceed,1.0
2103,combined,1.0
2104,failure,1.0
2105,needed,1.0
2106,pursue,1.0
2107,liquidity,1.0
2108,note 1,1.0
2109,inclusion,1.0
2110,derive,1.0
2111,commercialize,1.0
2112,extend,1.0
2113,benefits,1.0
2114,acquiring,1.0
2115,maintenance,1.0
2116,duration,1.0
2117,legal,1.0
2118,audit,1.0
2119,reflecting,1.0
2120,note,1.0
2121,increases,1.0
2122,attributable,1.0
2123,table,1.0
2124,august 2015,1.0
2125,premium,1.0
2126,preparing,1.0
2127,excess,1.0
2128,purchases,1.0
2129,plant,1.0
2130,facilitate,1.0
2131,enable,1.0
2132,additionally,1.0
2133,favor,1.0
2134,request,1.0
2135,depend,1.0
2136,decide,1.0
2137,pursuing,1.0
2138,choose,1.0
2139,seeking,1.0
2140,filing,1.0
2141,prosecuting,1.0
2142,maintaining,1.0
2143,enforcing,1.0
2144,emergence,1.0
2145,devote,1.0
2146,commercializing,1.0
2147,june,1.0
2148,remeasurement,1.0
2149,deferral,1.0
2150,defers,1.0
2151,unit,1.0
2152,narrow,1.0
2153,addresses,1.0
2154,issues,1.0
2155,asus,1.0
2156,selected,1.0
2157,holder,1.0
2158,settle,1.0
2159,yields,1.0
2160,collaborate,1.0
2161,brings,1.0
2162,june,1.0
2163,participated,1.0
2164,purchasing 141,1.0
2165,close,1.0
2166,charge,1.0
2167,excluding,1.0
2168,68 item2,1.0
2169,september 20,1.0
2170,submission,1.0
2171,discussed,1.0
2172,june,1.0
2173,occurred,1.0
2174,revaluation,1.0
2175,august 2019,1.0
2176,march 15,1.0
2177,noted,1.0
2178,september 30,1.0
2179,letters,1.0
2180,august 2016,1.0
2181,commence,1.0
2182,march 2017,1.0
2183,august 2027,1.0
2184,construction,1.0
2185,withdrawal,1.0
2186,note 9,1.0
2187,late,1.0
2188,reclassifications,1.0
2189,15 days,1.0
2190,concurrently,1.0
2191,scale,1.0
2192,nsp,1.0
2193,accessible,1.0
2194,december,1.0
2195,reconciliation,1.0
2196,sum,1.0
2197,march31,1.0
2198,adopt,1.0
2199,remainder,1.0
2200,adopting,1.0
2201,holders,1.0
2202,safe,1.0
2203,february 22,1.0
2204,march,1.0
2205,resignation,1.0
2206,validate,1.0
2207,manufacture,1.0
2208,supply,1.0
2209,delivery,1.0
2210,carry,1.0
2211,chooses,1.0
2212,cancel,1.0
2213,december,1.0
2214,procure,1.0
2215,expired,1.0
2216,premises,1.0
2217,replenished,1.0
2218,sooner,1.0
2219,terminate,1.0
2220,triggers,1.0
2221,redemption,1.0
2222,resale,1.0
2223,qualifications,1.0
2224,researching,1.0
2225,december,1.0
2226,exceeded,1.0
2227,objective,1.0
2228,ema,1.0
2229,mmitt,1.0
2230,population,1.0
2231,test,1.0
2232,populations,1.0
2233,tolerated,1.0
2234,comprised,1.0
2235,mortality,1.0
2236,orally,1.0
2237,combination,1.0
2238,lactam,1.0
2239,begin,1.0
2240,initiate,1.0
2241,suitable,1.0
2242,synthesis,1.0
2243,ready,1.0
2244,built,1.0
2245,utilize,1.0
2246,cros,1.0
2247,attributed,1.0
2248,move,1.0
2249,advancement,1.0
2250,march 14,1.0
2251,june,1.0
2252,collectively,1.0
2253,june30,1.0
2254,bringing,1.0
2255,june,1.0
2256,probable,1.0
2257,july,1.0
2258,cochlear,1.0
2259,note 10,1.0
